Login
Korro Bio, Inc. logo

Korro Bio, Inc.

korrobio.com

What Do They Do?

Develops RNA-editing genetic medicines, using oligonucleotides to repair or alter proteins for people with rare and common diseases.

How Do They Make Money?

Korro has no approved products or product-sale revenue. It earned collaboration revenue from Novo Nordisk under a research collaboration and license agreement; the agreement combines licensing with research work, with payment tied to the license and work performed over time.

FY2025 revenue

Who Are Their Customers?

Novo Nordisk is the named research collaborator and licensee; the reports do not describe how customers buy.

Do Revenues Turn Into Profits?

No. It lost $117.3M in FY2025.

Operating income, FY2025
−1906% of revenue
▼ −33% (Loss) vs FY2024 (−$91.9M, −4047%)
Net income, FY2025
−1834% of revenue
▼ −40% (Loss) vs FY2024 (−$83.6M, −3680%)
Free cash flow, FY2025
−1237% of revenue
▼ −1% (Loss) vs FY2024 (−$78M, −3434%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −100%
vs $1.1M in Q3 FY2025
Net income
▲ +3% (Loss)
vs −$18.1M in Q3 FY2025
  • Aug 19, 2026 Korro submitted to start KRRO-121’s first-in-human trial The proposed Phase 1/2 study would assess safety, tolerability, drug levels and effects in healthy volunteers and participants with urea cycle disorders.
  • Aug 6, 2026 Korro nominated KRRO-111 as an AATD development candidate The company said KRRO-121 remained on track to begin its first-in-human trial in the second half of 2026.

Shrinking. Revenue fell 54% in 4 years, from $14M in FY2021 to $6.4M in FY2025, about 18% a year.

From regenerative medicine to RNA editing The older report described small-molecule medicines that activate progenitor cells, with remyelination for multiple sclerosis as the focus. The latest report describes oligonucleotide medicines that edit RNA to repair or alter proteins across rare and common diseases.

Who Do They Compete With?

Competes with AIRNA, Beam Therapeutics, Prime Medicine, ProQR, Tessera Therapeutics, Verve Therapeutics, Wave Life Sciences, YolTech Therapeutics, Edigene, and Shape Therapeutics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support